Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elliot Shin

Family Medicine Las Vegas, NV Medical Doctor

NPI 1275554057 CMS profile 238957

888 S Rancho Dr, Las Vegas, NV 89106

Open in the dashboard

General payments

$10,921

59 records reported · program years 2019–2025

Research payments

$5,500

Paid to them · 25 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,095,164 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Elliot Shin of Las Vegas, NV is reported in the CMS Open Payments database as having received $10,921 across 59 general payments and $5,500 in research payments paid to them. Separately, studies naming them as principal investigator received $2,095,164 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,532 10
2025 Research $2,311 2
2024 General $69 2
2024 Research $1,978 14
2023 General $8,990 44
2023 Research $193 1
2022 General $109 1
2021 General $128 1
2019 General $92 1
2019 Research $1,018 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elliot Shin
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Elliot Shin were reported at $1,532. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Elliot Shin Family Medicine median Middle half National median
2019 $92 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $128 $137 $35–$551 $132
2022 $109 $137 $37–$512 $149
2023 $8,990 $149 $42–$545 $160
2024 $69 $156 $44–$560 $164
2025 $1,532 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $4,568 36 payments
  2. Chiesi USA, Inc. $3,774 5 payments
  3. Biogen, Inc. $1,816 13 payments
  4. Eli Lilly and Company $434 2 payments
  5. SI-BONE, Inc. $128 1 payment
  6. Galderma Laboratories, L.P. $109 1 payment
  7. Novo Nordisk Inc $92 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $8,379 25 payments
  2. Food and Beverage $2,542 34 payments
Products named General payments · program years 2019–2025
  1. IFUSE IMPLANT $128 1 payment
  2. Saxenda $92 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,504 3 payments
  2. Sanofi US Services Inc. $1,978 14 payments
  3. Gilead Sciences, Inc. $1,018 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

22

Median for Family Practice: 1,826

Drug cost

$6,765

Median for Family Practice: $120,094

Branded share of claims

100%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humalog Kwikpen U-200 Insulin Lispro Brand 11 $5,635
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $1,130

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record